These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 28566898)

  • 1. Antimicrobial susceptibility testing before first-line treatment for
    Cosme A; Montes M; Ibarra B; Tamayo E; Alonso H; Mendarte U; Lizasoan J; Herreros-Villanueva M; Bujanda L
    World J Gastroenterol; 2017 May; 23(18):3367-3373. PubMed ID: 28566898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies.
    Cosme A; Torrente Iranzo S; Montes Ros M; Fernández-Reyes Silvestre M; Alonso Galán H; Lizasoain J; Bujanda L
    Helicobacter; 2019 Feb; 24(1):e12557. PubMed ID: 30460730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance.
    Cosme A; Lizasoan J; Montes M; Tamayo E; Alonso H; Mendarte U; Martos M; Fernández-Reyes M; Saraqueta C; Bujanda L
    Helicobacter; 2016 Feb; 21(1):29-34. PubMed ID: 25982426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients.
    Sun WH; Ou XL; Cao DZ; Yu Q; Yu T; Hu JM; Zhu F; Sun YL; Fu XL; Su H
    World J Gastroenterol; 2005 Apr; 11(16):2477-81. PubMed ID: 15832421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.
    Peitz U; Sulliga M; Wolle K; Leodolter A; Von Arnim U; Kahl S; Stolte M; Börsch G; Labenz J; Malfertheiner P
    Aliment Pharmacol Ther; 2002 Feb; 16(2):315-24. PubMed ID: 11860415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
    Borody TJ; Pang G; Wettstein AR; Clancy R; Herdman K; Surace R; Llorente R; Ng C
    Aliment Pharmacol Ther; 2006 Feb; 23(4):481-8. PubMed ID: 16441468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy.
    Huang AH; Sheu BS; Yang HB; Huang CC; Wu JJ; Lin XZ
    J Formos Med Assoc; 2000 Sep; 99(9):704-9. PubMed ID: 11000734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group.
    Fock KM; Chelvam P; Lim SG
    Aliment Pharmacol Ther; 2000 Feb; 14(2):225-31. PubMed ID: 10651664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin.
    Gisbert JP; Pérez-Aisa A; Castro-Fernández M; Barrio J; Rodrigo L; Cosme A; Gisbert JL; Marcos S; Moreno-Otero R
    Dig Liver Dis; 2010 Apr; 42(4):287-90. PubMed ID: 19632166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
    Bago J; Halle ZB; Strinić D; Kućisec N; Jandrić D; Bevanda M; Tomić M; Bilić A
    Wien Klin Wochenschr; 2002 Jun; 114(12):448-53. PubMed ID: 12422579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic].
    Gisbert JP; Boixeda D; Martín de Argila C; Redondo C; Moreno L; Abraira V; García Plaza A
    Med Clin (Barc); 1998 Jan; 110(1):1-5. PubMed ID: 9527978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes.
    Yang YJ; Wu CT; Ou HY; Lin CH; Cheng HC; Chang WL; Chen WY; Yang HB; Lu CC; Sheu BS
    Ann Med; 2017 Sep; 49(6):479-486. PubMed ID: 28266875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study.
    Katelaris PH; Adamthwaite D; Midolo P; Yeomans ND; Davidson G; Lambert J
    Aliment Pharmacol Ther; 2000 Jun; 14(6):751-8. PubMed ID: 10848659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
    Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
    Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
    Chuah SK; Liang CM; Lee CH; Chiou SS; Chiu YC; Hu ML; Wu KL; Lu LS; Chou YP; Chang KC; Kuo CH; Kuo CM; Hu TH; Tai WC
    Medicine (Baltimore); 2016 May; 95(19):e3586. PubMed ID: 27175657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains.
    Houben MH; Hensen EF; Rauws EA; Hulst RW; Hoff BW; Ende AV; Kate FJ; Tytgat GN
    Aliment Pharmacol Ther; 1999 Jul; 13(7):883-9. PubMed ID: 10383522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?
    Lerang F; Moum B; Haug JB; Tolås P; Breder O; Aubert E; Høie O; Søberg T; Flaaten B; Farup P; Berge T
    Am J Gastroenterol; 1997 Feb; 92(2):248-53. PubMed ID: 9040200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial.
    Ramas M; Donday MG; McNicholl AG; Gisbert JP
    Gastroenterol Hepatol; 2017 Dec; 40(10):658-662. PubMed ID: 28780968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.